Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by AAVantgarde

News headline image
AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde to Present at the 44th Annual J.P. Morgan Healthcare Conference
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde announces 3 presentations at ESGCT 2025 annual meeting
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde presents updated positive clinical data from its AAVB-081 program for Usher 1B at EURetina 2025
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde to Present Updated Clinical Data from LUCE-1 Study at EURetina 2025
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde presents positive clinical data from its AAVB-081 program for Usher 1B and preclinical data from its AAVB-039 program for Stargardt at the ARVO 2025 annual meeting
From AAVantgarde
Via GlobeNewswire
News headline image
AAVantgarde appoints Mr. Rasmus Holm-Jorgensen as Chief Financial Officer
From AAVantgarde
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.